Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

Abstract

Thiopurine methyltransferase (TPMT) catalyses the S-methylation of thiopurines, including 6-mercaptopurine and 6-thioguanine. TPMT activity exhibits genetic polymorphism, with about 1/300 inheriting TPMT deficiency as an autosomal recessive trait. If treated with standard doses of thiopurines, TPMT-deficient patients accumulate excessive thioguanine nucleotides in hematopoietic tissues, leading to severe hematological toxicity that can be fatal. However, TPMT-deficient patients can be successfully treated with a 10- to 15-fold lower dosage of these medications. The molecular basis for altered TPMT activity has been defined, with rapid and inexpensive assays available for the three signature mutations which account for the majority of mutant alleles. TPMT genotype correlates well with in vivo enzyme activity within erythrocytes and leukemic blast cells and is clearly associated with risk of toxicity. The impact of 6-mercaptopurine dose intensity is also being clarified as an important determinate of event-free survival in childhood leukemia. In addition, there are emerging data that TPMT genotype may influence the risk of secondary malignancies, including brain tumors and acute myelogenous leukemia. Ongoing studies aim to clarify the influence of TPMT on thiopurine efficacy, acute toxicity, and risk for delayed toxicity. Together, these advances hold the promise of improving the safety and efficacy of thiopurine therapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE . Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia Blood 1999 93: 2817–2823

    CAS  Google Scholar 

  2. McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BES . Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia Br J Haematol 1999 105: 696–700

    Article  CAS  Google Scholar 

  3. Krynetski EY, Evans WE . Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm Pharmaceut Res 1999 16: 342–349

    Article  CAS  Google Scholar 

  4. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV Evans WE . Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms Pharmacogenetics 1996 6: 279–290

    Article  CAS  Google Scholar 

  5. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM . Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia Lancet 1990 336: 225–229

    Article  CAS  Google Scholar 

  6. Evans WE, Horner M, Chu YO, Kalwinsky D, Roberts WM . Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltranferase-deficient child with acute lymphoblastic leukemia J Pediatr 1991 119: 985–989

    Article  CAS  Google Scholar 

  7. McLeod HL, Miller DR, Evans WE . Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart-transplant recipient Lancet 1993 341: 1151

    Article  CAS  Google Scholar 

  8. Schutz E, Gummert J, Mohr F, Oellerich M . Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient Lancet 1993 341: 436

    Article  CAS  Google Scholar 

  9. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE . Thiopurine methyltransferase activity in American white subjects and black subjects Clin Pharm Ther 1994 55: 15–20

    Article  CAS  Google Scholar 

  10. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE . Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance Ann Intern Med 1997 126: 608–616

    Article  CAS  Google Scholar 

  11. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, ParkHah JO, Iven H, Schmiegelow K, Branum E, Obrain J, Weinshilboum R . Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms Clin Pharmacol Ther 1997 62: 60–73

    Article  CAS  Google Scholar 

  12. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE . Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians Am J Hum Genet 1993 58: 694–702

    Google Scholar 

  13. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE . Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity Proc Natl Acad Sci USA 1997 94: 6444–6449

    Article  CAS  Google Scholar 

  14. delaMoureyre CSV, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, LoGuidice JM, Broly F . Detection of known and new mutations in the thiopurine S-methyltransferase gene bysingle-strand conformation polymorphism analysis Hum Mutat 1998 12: 177–185

    Article  CAS  Google Scholar 

  15. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM . Human thiopurine methyltransferase pharmacogenetics–kindred with a terminal exon splice junction mutation that results in loss of activity J Clin Invest 1998 101: 1036–1044

    Article  CAS  Google Scholar 

  16. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE . A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase Proc Natl Acad Sci USA 1995 92: 949–953

    Article  CAS  Google Scholar 

  17. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, d'Azzo A, Krynetski EY, Evans WE . Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C Pharmacogenetics 1999 9: 641–650

    Article  CAS  Google Scholar 

  18. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynestski EY, Evans WE . Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans Clin Pharmacol Ther 1998 64: 46–51

    Article  CAS  Google Scholar 

  19. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE . Polymorphism of the thiopurine S-methyltransferase gene in African–Americans Hum Mol Gen 1999 8: 371–376

    Article  CAS  Google Scholar 

  20. Ameyaw MM, Collie-Duguid ESR, Powrie RH, Ofori-Adjei D, McLeod HL . Thiopurine methyltransferase alleles in British and Ghanaian populations Hum Mol Gen 1999 8: 367–370

    Article  CAS  Google Scholar 

  21. Collie-Duguid ESR, Prichard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL . The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations Pharmacogenetics 1999 9: 37–42

    Article  CAS  Google Scholar 

  22. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, Booth L, Collie-Duguid ESR . Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan subjects Pharmacogenetics 1999 9: 773–776

    Article  CAS  Google Scholar 

  23. Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, Konishi F, Maeda H, Yamakido M . Allelotype frequency of the thiopurine methyltransferase gene in Japanese Pharmacogenetics (in press)

  24. Coulthard SA, Howell C, Robson J, Hall AG . The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia Blood 1998 92: 2856–2862

    CAS  PubMed  Google Scholar 

  25. delaMoureyre CSV, Debuysere H, Mastain B, Vinner E, Marez D, LoGuidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo EM, Pol A, Lhermitte M, Lafitte JJ, Libersa C, Broly F . Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population Br Pharmacol 1998 125: 879–887

    Article  Google Scholar 

  26. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-duguid ESR, Reid DM . Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 1998 129: 716–718

    Article  CAS  Google Scholar 

  27. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE . Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic-leukemia Blood 1995 85: 1897–1902

    CAS  Google Scholar 

  28. Relling MV, Hancock HL, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH Evans WE . Intolerance to mercaptopurine therapy related to heterozygosity at the thiopurine methyltransferase gene locus J Natl Cancer Inst 1999 91: 2001–2008

    Article  CAS  Google Scholar 

  29. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH . High incidence of secondary brain tumours after radiotherapy and antimetabolites Lancet 1999 354: 34–39

    Article  CAS  Google Scholar 

  30. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behn FG, Pui CH . Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia Leukemia 1998 12: 346–352

    Article  CAS  Google Scholar 

  31. Thomsen JB, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, Andersen JB, Schmiegelow . Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells Cancer 1999 86: 1080–1086

    Article  CAS  Google Scholar 

  32. Krynetski EY, Evans WE . Pharmacogenetics of cancer therapy: getting personal Am Hum Genet 1998 63: 11–16

    Article  CAS  Google Scholar 

  33. Kitchen BJ, Moser A, Lowe E, Balis FM, Widemann B, Anderson L, Strong J, Blaney SM, Berg SL, O'Brien M, Adamson PC . Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine J Pharmacol Exp Ther 1999 2: 870–874

    Google Scholar 

  34. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE . Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase Mol Pharmacol 1995 6: 1141–1147

    Google Scholar 

Download references

Acknowledgements

This work was supported by Aberdeen Royal Infirmary Endowments, Cancer Center Core grant CAZ1765, by NIH grants R37 CA 36401 and R01 CA51001, and American Lebanese Syrian Associated Charities (ALSAC). The efforts of Kate Smith in manuscript preparation are greatly appreciated.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLeod, H., Krynetski, E., Relling, M. et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14, 567–572 (2000). https://doi.org/10.1038/sj.leu.2401723

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401723

Keywords

This article is cited by

Search

Quick links